Lisata prelim data in Phase 2 pancreatic cancer trial

 Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Data reported positive trend in overall survival, including 4 complete responses observed in the certepetide treatment group compared to none in placebo group

Data from Cohort B expected in the coming months, with full data from both cohorts to be reported thereafter

https://www.globenewswire.com/news-release/2025/01/22/3013425/18623/en/Lisata-Therapeutics-Reports-Encouraging-Preliminary-Cohort-A-Data-from-the-AGITG-led-Phase-2-ASCEND-Trial-Evaluating-Certepetide-with-Standard-of-Care-Chemotherapy-in-Metastatic-Pa.html